Aquestive nabs FDA OK for oral film version of generic ALS drug
The FDA has given Aquestive Therapeutics the green light to market Exservan, its oral film formulation of a decades-old treatment for amyotrophic lateral sclerosis.
Back in 1995 riluzole became the first FDA-approved therapy for ALS, which remains incurable. Its exact mechanism of action is unknown but it’s been proposed that the drug blocks the release of glutamate from nerve cells, thereby alleviating glutamate-induced deterioration. As a result, the original drug was shown to delay symptoms and even death.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.